A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
- 7 April 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (588)
- https://doi.org/10.1126/scitranslmed.aaz6804
Abstract
Insufficient T cell infiltration into noninflamed tumors, such as hepatocellular carcinoma (HCC), restricts the effectiveness of immune-checkpoint blockade (ICB) for a subset of patients. Epigenetic therapy provides further opportunities to rewire cancer-associated transcriptional programs, but whether and how selective epigenetic inhibition counteracts the immune-excluded phenotype remain incompletely defined. Here, we showed that pharmacological inhibition of histone deacetylase 8 (HDAC8), a histone H3 lysine 27 (H3K27)–specific isozyme overexpressed in a variety of human cancers, thwarts HCC tumorigenicity in a T cell–dependent manner. The tumor-suppressive effect of selective HDAC8 inhibition was abrogated by CD8+ T cell depletion or regulatory T cell adoptive transfer. Chromatin profiling of human HDAC8-expressing HCCs revealed genome-wide H3K27 deacetylation in 1251 silenced enhancer-target gene pairs that are enriched in metabolic and immune regulators. Mechanistically, down-regulation of HDAC8 increased global and enhancer acetylation of H3K27 to reactivate production of T cell–trafficking chemokines by HCC cells, thus relieving T cell exclusion in both immunodeficient and humanized mouse models. In an HCC preclinical model, selective HDAC8 inhibition increased tumor-infiltrating CD8+ T cells and potentiated eradication of established hepatomas by anti–PD-L1 therapy without evidence of toxicity. Mice treated with HDAC8 and PD-L1 coblockade were protected against subsequent tumor rechallenge as a result of the induction of memory T cells and remained tumor-free for greater than 15 months. Collectively, our study demonstrates that selective HDAC8 inhibition elicits effective and durable responses to ICB by co-opting adaptive immunity through enhancer reprogramming.Keywords
Funding Information
- Terry Fox Foundation
- Theme-Based Research Scheme (T11-706/18-N)
- University Grants Committee through the Collaborative Research Fund (C4045-18W)
- The Focused Innovations Scheme-Scheme B from the Chinese University of Hong Kong (1907309)
- The Li Ka Shing Foundation
This publication has 72 references indexed in Scilit:
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 2013
- Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostatBreast Cancer Research, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and CufflinksNature Protocols, 2012
- The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patientsAmerican Journal of Hematology, 2012
- Integrative genomics viewerNature Biotechnology, 2011
- Clinical Toxicities of Histone Deacetylase InhibitorsPharmaceuticals, 2010
- Histone modifications at human enhancers reflect global cell-type-specific gene expressionNature, 2009
- AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiencyNature Medicine, 2009
- Model-based Analysis of ChIP-Seq (MACS)Genome Biology, 2008